Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01372150 · ClinicalTrials.gov registry record · Phase 3
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 340
- Enrollment target
NCT01372150: Completed Phase 3 study, sponsored by Pfizer.
NCT01372150 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 340 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01372150, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 340 participants
- Enrollment target
Study Summary
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
Primary Outcome
Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.
Interventions
- DRUG placebo
- DRUG fluoxetine
- DRUG desvenlafaxine succinate sustained release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2011-11-17 |
| Est. Completion | 2015-03-20 |
| Phase | Phase 3 |
What the finished NCT01372150 record still lists
NCT01372150 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01372150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01372150 about?
NCT01372150 is a clinical study titled "A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD". This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
What is the current status of trial NCT01372150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 340 participants. The study started on 2011-11-17. Estimated completion is 2015-03-20.
What interventions are being tested in trial NCT01372150?
The interventions under investigation include: placebo (DRUG), fluoxetine (DRUG), desvenlafaxine succinate sustained release (DRUG).
Who is sponsoring clinical trial NCT01372150?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01372150's enrollment target sits among peer trials
340 1053rd of 2000 higher than 945 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI